-->

Company Registry

Q Therapeutics Inc (AKA:Q Holdings Inc)
Profile last edited on: 6/17/2021

Cell therapies for neurodegenerative diseases
Year Founded
2002
First SBIR Year
2004
Latest SBIR Award
2010
Program Status
Inactive

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

615 Arapeen Drive Suite 102
Salt Lake City, UT 84108
   (801) 582-5400
   N/A
   www.qthera.com
Multiple Locations:   
Congressional District:   02
County:   Salt Lake

Public Profile

Q Therapeutics, Inc. is organizeda rounf development of glial cell-based therapeutic products for central nervous system (CNS) disorders in which a disease or injury inhibits normal myelin growth and enzyme performance. The direct source of more than 90% of cells in the mammalian nervous system Glial cells are essential for maintaining its normal functions. Insufficient or defective myelin and/or enzyme function is responsible disorders such as multiple sclerosis, cerebral palsy, leukodystrophies, and certain lysosomal storage disorders and prevents recovery from white-matter stroke and spinal cord injury. Q Therapeutics’ technologies allow for GMP scale-up and treatment of large population disorders while holding the promise of restorative, not just preventive, therapy for these CNS conditions. Products currently under development are targeted to treat multiple sclerosis (MS), transverse myelitis, ALS (Lou Gehrig's Disease), cerebral palsy, spinal cord injury, traumatic brain injury, stroke, Parkinson's Disease and Alzheimer's Disease. In Spring 2018, the firm formed a Joint Venture with REPROCELL Inc., Japan’s first induced pluripotent stem cell (iPSC) company,. Designated MAGiQ Therapeutics, Inc., a Japanese joint venture company. MAGiQ will develop iPSC-derived, glial-restricted progenitor cells (GRPs), in collaboration with Q Therapeutics and REPROCELL, to treat demyelinating and degenerative diseases of the CNS.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
10-14
Revenue Range
1M-1.5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
---
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Deborah A Eppstein -- President; Chief Executive Officer; Director

  Steven J Borst -- Chief Financial Officer; Vice President, Corporate Development

  James T Campanelli -- Vice President, Research & Development

  Mani Ramaswami --

  Mahendra Rao -- Scientific Founder

  Robert W Sandrock -- Senior Scientist